miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Warsh's Fed 'regime change' may require patience, consensus

View original at finance.yahoo.com
Warsh's Fed 'regime change' may require patience, consensus (Bloomberg) -- Kevin Warsh has vowed to usher in “regime change” as the new chair of the Federal Reserve, but Fed watchers say there are limits to how much he can revamp on his own — and that even in areas where he can make sweeping reform, it might be smarter…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • One of Warsh's primary tasks will be building FOMC consensus to lower interest rates when appropriate

    60% confidence
  • Warsh has vowed to usher in 'regime change' as the new Federal Reserve chair

    60% confidence
  • With inflation accelerating and the labor market stabilizing, FOMC policymakers are comfortable keeping rates on hold

    60% confidence
  • Some FOMC policymakers are pushing for the Fed to signal its next move is just as likely to be a rate hike as a rate cut

    60% confidence
  • If lowering rates is Warsh's top priority, he will have a strong incentive to avoid alienating FOMC members and to curry goodwill

    60% confidence
  • Warsh has vowed to keep monetary policy independent from politics

    60% confidence
  • Warsh has long been an advocate for shrinking the Fed's asset portfolio

    60% confidence
  • Trump has made it no secret that he expects Warsh to lower interest rates

    60% confidence

Data points we hold from this source

Federal Reserve · cash6.7 trillion_USD

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Warsh's Fed 'regime change' may require patience, consensus — Source | Via News | es.VIA.NEWS